• Dual-Action Inhibitors and p38α Dephosphorylation

  2026-09-01

  The reference preprint shows that selected kinase inhibitors can do more than block p38α catalytic activity: they can also accelerate WIP1-mediated dephosphorylation by reshaping the kinase activation loop. Biochemical assays and crystal structures connect this dual action to exposure of the activation-loop phosphothreonine, offering a mechanistic framework for designing more selective kinase-directed interventions.

• Vancomycin hydrochloride: Assays, Workflows & Tips

  2026-09-01

  Use Vancomycin hydrochloride as a defined Gram-positive benchmark for susceptibility testing, selective culture workflows, resistance tracking, and translational infection studies. This guide connects practical assay setup with longitudinal PKPD concepts that reveal adaptive resistance beyond a single MIC value.

• Rotigotine: Workflow for PD Research

  2026-08-31

  Rotigotine is a dopamine D2/D3 receptor agonist for linking receptor pharmacology with neuroprotection, motor phenotyping, and depression-related behavioral assays. This workflow explains how to select exposure windows, separate antidepressant-like activity from locomotor stimulation, and troubleshoot formulation and route-specific variables.

• EPZ5676: DOT1L Inhibitor Workflow Guide

  2026-08-31

  EPZ5676 combines picomolar biochemical binding with strong selectivity for DOT1L, making it a focused tool for connecting H3K79 methylation to MLL-fusion leukemia biology. This guide translates that profile into enzyme assays, MV4-11 cell workflows, orthogonal epigenetic readouts, and practical troubleshooting.

• Mubritinib (TAK 165) for OXPHOS Assays

  2026-08-30

  Mubritinib (TAK 165) is a versatile research probe for separating mitochondrial complex I dependence from historical HER2 activity. This guide shows how to apply it in AML, PEL, and HER2-oriented assays while improving solubility control, endpoint selection, and mechanism validation.

• COX-2 Timing in Venom-Induced Muscle Repair

  2026-08-29

  A Microvascular Research study shows that COX-2 has a time-dependent role after Bothrops asper venom damages skeletal muscle microvasculature: its early activity helps limit ischemia, whereas early pathway inhibition later enhances proangiogenic remodeling. The findings position lumiracoxib as a mechanistic tool for studying how prostaglandin signaling coordinates vascular injury, ischemia, and revascularization.

• AZD8055 Protocol Guide for Dual mTOR Inhibition

  2026-08-28

  AZD8055 is a selective ATP-competitive mTOR inhibitor for preclinical studies requiring coordinated interrogation of mTORC1 and mTORC2 signaling. This guide focuses on solvent handling, assay design, pathway verification, and interpretation limits; it is not intended to support clinical efficacy claims or protocols requiring a water-soluble compound.

• Cediranib (AZD2171) for VEGFR Assays

  2026-08-28

  Use Cediranib (AZD2171) to separate VEGFR-driven signaling, angiogenic behavior, growth arrest, and cell killing in cancer research. This practical guide combines pathway pharmacology with assay-design principles that improve interpretation beyond a single viability endpoint.

• Mubritinib (TAK 165): From HER2 to Complex I

  2026-08-27

  Mubritinib is best understood not as a conventional HER2 inhibitor, but as a mechanistically distinctive mitochondrial complex I inhibitor with translational potential in oxidative phosphorylation-dependent malignancies. This thought-leadership analysis connects the compound’s toxicophore, selective activity in AML and PEL models, cardiac safety implications, and practical study-design priorities.

• Imatinib (STI571): From Kinase Tool to Translational Lens

  2026-08-27

  Imatinib (STI571) is more than a pathway inhibitor: it is a controlled perturbation tool for connecting Abl, PDGF receptor, and c-Kit signaling with disease phenotypes. This thought-leadership guide outlines how translational researchers can deploy it across kinase assays, CML models, and increasingly complex tumor systems.

• BFH772 (VEGFR2 inhibitor): Workflow Guide

  2026-08-26

  BFH772 is a selective small-molecule VEGFR2 inhibitor for biochemical, cellular, and tumor angiogenesis research where organic-solvent handling and receptor-focused experiments are acceptable. It should not be selected for water-based formulations, broad-spectrum kinase inhibition, or clinical treatment decisions without additional validated evidence.

• Cabozantinib: From Kinase Blockade to Adaptive Networks

  2026-08-26

  Cabozantinib, also known as XL184, offers more than broad receptor tyrosine kinase inhibition. This thought-leadership analysis translates phosphoproteomic evidence from renal cell carcinoma into practical guidance for modeling acute response, chronic adaptation, angiogenesis, motility, and translational biomarker strategy.

• BFH772 (VEGFR2 inhibitor): Workflow Guide

  2026-08-25

  BFH772 is a selective small-molecule VEGFR2 inhibitor for pathway-focused kinase, cellular, and tumor angiogenesis research. Its water insolubility and organic-solvent dependence make it unsuitable for protocols requiring direct aqueous formulation or broad-spectrum kinase inhibition without additional validation.

• AI-10-49: CBFβ-SMMHC Inhibitor Workflows

  2026-08-25

  AI-10-49 enables mechanism-focused acute myeloid leukemia research by disrupting the CBFβ-SMMHC–RUNX1 interaction and connecting target engagement with transcriptional and viability readouts. This practical guide covers dose design, chromatin immunoprecipitation, N-MYC/eIF4G1 analysis, troubleshooting, and preclinical study planning.

• Drug Response Metrics in Cancer In Vitro

  2026-08-24

  Hannah Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. Its key practical contribution is a more resolved framework for separating growth inhibition from cell killing and interpreting their different proportions and timing in vitro.

8078 records 1/539 page Next 12345 下5页 Last page